6OM Stock Chart & Stats
€2.62
€0.30(2.31%)
At close: 4:00 PM EST
€2.62
€0.30(2.31%)
Day’s Range― - ―
52-Week Range€1.51 - €6.95
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€232.29M
Enterprise Value€2.01K
Total Cash (Recent Filing)€336.88M
Total Debt (Recent Filing)€2.17B
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Jul 31, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.05
Shares Outstanding76,583,700
10 Day Avg. Volume267
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.47
Price to Sales (P/S)0.08
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.52Price Target Upside72.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.6
Revenue Forecast (FY)€2.21B
Bulls Say, Bears Say
Bulls Say
Accounting Adjustment And Reported EarningsAnalyst notes that reclassification of certain add‑backs into adjusted operating income increased adjusted earnings per share without materially changing EBITDA, supporting headline profitability metrics.
Operational Initiatives And Technology InvestmentsAnalyst points to management's tighter operational focus, investments in technology, and improved collections as measures likely to reduce costs and improve cash generation.
Product-line Revenue StrengthAnalyst highlights robust performance in sleep apnea, urology, and ostomy businesses that underpin revenue resilience and can partially offset weakness in respiratory products.
Bears Say
Capital Structure And Leverage RiskAnalyst flags elevated debt levels and capital structure concerns that increase financial risk and limit flexibility for strategic investments or debt reduction.
Competitive, Reimbursement And Product Substitution PressuresAnalyst cautions that competitive bidding, a shift to pharmacy channels for diabetes fulfillment, adoption of GLP‑1 therapies, and reimbursement pressures may constrain long‑term revenue growth and pricing power.
Customer Loss And Stranded Separation CostsAnalyst warns that the loss of a major customer and stranded costs from the company's separation could continue to depress margins and weigh on near‑term profitability.
Accendra Health News
6OM FAQ
What was Accendra Health’s price range in the past 12 months?
Accendra Health lowest stock price was €1.51 and its highest was €6.95 in the past 12 months.
What is Accendra Health’s market cap?
Accendra Health’s market cap is €232.29M.
When is Accendra Health’s upcoming earnings report date?
Accendra Health’s upcoming earnings report date is Jul 31, 2026 which is in 12 days.
How were Accendra Health’s earnings last quarter?
Accendra Health released its earnings results on May 11, 2026. The company reported -€0.035 earnings per share for the quarter, beating the consensus estimate of -€0.086 by €0.051.
Is Accendra Health overvalued?
According to Wall Street analysts Accendra Health’s price is currently Undervalued.
Does Accendra Health pay dividends?
Accendra Health does not currently pay dividends.
What is Accendra Health’s EPS estimate?
Accendra Health’s EPS estimate is -0.07.
How many shares outstanding does Accendra Health have?
Accendra Health has 76,583,700 shares outstanding.
What happened to Accendra Health’s price movement after its last earnings report?
Accendra Health reported an EPS of -€0.035 in its last earnings report, beating expectations of -€0.086. Following the earnings report the stock price went down -5.096%.
Which hedge fund is a major shareholder of Accendra Health?
Currently, no hedge funds are holding shares in DE:6OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Accendra Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.52 (72.35% Upside)
€4.52 (72.35% Upside)
Blogger Sentiment
Bullish
DE:6OM Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.19%
12-Months-Change
Fundamentals
Return on Equity
264.54%
Trailing 12-Months
Asset Growth
-50.25%
Trailing 12-Months
Company Description
Accendra Health
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.
6OM Stock 12 Month Forecast
Average Price Target
€4.52
▲(72.35% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
McKesson
―
Guardian Pharmacy Services, Inc. Class A
―









